Meine Merkliste  

3.482 Aktuelle Fachpublikationen von Future Medicine


Sie können Ihre Recherche weiter verfeinern. Wählen Sie aus dem linken Bereich passende Suchfilter aus, um Ihre Ergebnisse gezielt einzugrenzen.

Cost–effectiveness analysis of personalized antiplatelet therapy in patients with acute coronary syndrome

11.05.2016 | Minghuan Jiang; Joyce HS You, Pharmacogenomics, 2016

Aim: This study aimed to compare the clinical and economic outcomes of pharmacogenetic-guided (PG-guided) and platelet reactivity testing-guided antiplatelet therapy for patients with acute coronary syndrome undergoing percutaneous coronary intervention. Methods: A decision-analytic model was ...


Pharmacogenetic aspects of the treatment of Type 2 diabetes with the incretin effect enhancers

11.05.2016 | Ivan Tkáč; Ivana Gotthardová, Pharmacogenomics, 2016

Incretin effect enhancers are drugs used in the treatment of Type 2 diabetes and include GLP-1 receptor agonists and dipeptidyl peptidase-4 inhibitors (gliptins). Variants in several genes were shown to be involved in the physiology of incretin secretion. Only two gene variants have evidence also ...


Managing tuberculosis infection in children in the USA: an update

10.05.2016 | Andrea T Cruz; Jeffrey R Starke, Future Microbiology, 2016

The rate of tuberculosis (TB) disease has steadily declined in the last two decades in the USA, and over two-thirds of all cases now occur in foreign-born persons. Further declines in the incidence of TB will be most impacted by identifying and treating persons with TB infection. However, ...


Development of a rapid diagnostic assay based on magnetic bead purification of OXA-β-lactamase mRNA

10.05.2016 | Christian Brandt; Esther Zander; Yvonne Pfeifer; Sascha D Braun; Ralf Ehricht; Oliwia Makarewicz; Mathias W Pletz, Future Microbiology, 2016

Aim: To countermeasure the global spread of β-lactamases, we developed a rapid molecular test for the highly variable OXA-β-lactamases that allows minimizing the time to effective treatment. Methods: OXA-mRNA was specifically enriched from total RNA using group-specific biotinylated DNA probes ...


Oritavancin: a long-acting antibacterial lipoglycopeptide

10.05.2016 | Achim J Kaasch; Harald Seifert, Future Microbiology, 2016

Oritavancin is a new lipoglycopeptide antibacterial agent with an exceptionally long terminal half-life and a rapid bactericidal effect. Multiple mechanisms of action lead to a broad activity against Gram-positive bacteria, such as staphylococci, streptococci and enterococci, including ...


Cross-talk and specificity in two-component signal transduction pathways

09.05.2016 | Ruchi Agrawal; Bikash Kumar Sahoo; Deepak Kumar Saini, Future Microbiology, 2016

Two-component signaling systems (TCSs) are composed of two proteins, sensor kinases and response regulators, which can cross-talk and integrate information between them by virtue of high-sequence conservation and modular nature, to generate concerted and diversified responses. However, TCSs have ...


Phosphatases are emerging as novel druggable targets in Plasmodium

09.05.2016 | Jamal Khalife; Christine Pierrot, Future Microbiology, 2016

Future Microbiology Ahead of Print.


Gemmata species: Planctomycetes of medical interest

09.05.2016 | Rita Aghnatios; Michel Drancourt, Future Microbiology, 2016

The Planctomycetes genus Gemmata is represented by both uncultured organisms and cultured Gemmata obscuriglobus and ‘Gemmata massiliana’ organisms. Their plasmidless 9.2Mb genomes encode a complex cell plan, cell signaling capacities, antibiotic and trace metal resistance and multidrug ...


Could physical exercise help modulate the gut microbiota in chronic kidney disease?

09.05.2016 | Marta Esgalhado; Natália A Borges; Denise Mafra, Future Microbiology, 2016

Chronic kidney disease (CKD) patients have several metabolic disorders caused by chronic oxidative stress and inflammation. The imbalance of gut microbiota has been identified as a factor that may contribute to the development of these disorders, which can promote cardiovascular disease in CKD ...


Membrane-targeting AM-0016 kills mycobacterial persisters and shows low propensity for resistance development

09.05.2016 | Devika Mukherjee; Hanxun Zou; Shouping Liu; Roger Beuerman; Thomas Dick, Future Microbiology, 2016

Aim: To test the hypothesis that targeting the cytoplasmic membrane may be an effective way to kill persister mycobacteria and delay the emergence of resistance. Methods:In vitro activity of AM-0016, a novel xanthone-based antibacterial, was assessed against growing and persister tubercle ...


Seite 3 von 349
Suche per e-Mail abonnieren

Sie erhalten passend zu Ihrer Suche die neusten Suchergebnisse per E-Mail. Dieser Service ist für Sie kostenlos und kann jederzeit abbestellt werden.

Ihr Bowser ist nicht aktuell. Microsoft Internet Explorer 6.0 unterstützt einige Funktionen auf Chemie.DE nicht.